Compared with other malignancies, the protective effect of metformin on colorectal neoplasms appears to be comparable or slightly stronger and may reflect both systemic effects, such as improved insulin sensitivity and reduced inflammation, and tissue-specific mechanisms in the colorectal epithelium. The gene discussed is INS; the disease is colorectal neoplasm.